Modelled Impact of a Multi-Cancer Early Detection Screening Programme on Cancer Treatment in Eng

• The report presents a modelling exercise to explore how introducing a multi-cancer early detection (MCED) screening programme in England could reshape cancer treatment patterns across 19 cancer types detectable by the Galleri MCED test.
• Two modelling strata are used: an initial prevalent screening round for individuals aged 50–79 and a steady-state programme with annual screening from ages 50 to 79.
• The modelling anchors on stage-specific incidence changes predicted by an interception (natural history) model and couples these with observed, population-level treatment patterns by stage for the 19 cancers diagnosed 2014–2019.
• Data inputs derive from national health data sets, notably treatment flags for resection, radiotherapy, and systemic anti-cancer therapy (SACT) in the 18 months post-diagnosis, linked to incident cancer cases by stage.
• The study purpose is to estimate how MCED screening could shift the utilization of major treatment modalities (surgery, radiotherapy, cytotoxic and non-cytotoxic SACT) and to highlight potential implications for service delivery and workforce planning, acknowledging the need to align screening benefits with timely and appropriate treatment pathways.

The 2014–2019 window was chosen to minimize COVID-19–related distortions in cancer services.

These reflect the first 18 months following diagnosis and include adjuvant and neo-adjuvant treatments, with duplicates or multiple occurrences for the same cancer limited to a single observation per tumour.

The study distinguished cytotoxic versus non-cytotoxic SACT, with cytotoxic SACT defined by the presence of cytotoxic drugs in the earliest regimen; immunotherapy and targeted therapies were categorized as non-cytotoxic SACT.

In some instances, particularly with multiple tumours in the same 18-month window, intent could not be definitively assigned and defaulted to palliative in a few cases.

Participation was assumed at 70% for the screening scenarios, with a separate scenario at 100% participation to illustrate maximum potential effects.

This yielded estimated absolute and relative changes in the numbers of cancers treated with resection, radiotherapy (overall and segmented by curative vs palliative intent), and SACT (cytotoxic and non-cytotoxic).

• The analysis relies on cancer incidence data for England from 2014–2019, covering 19 cancer types detectable by Galleri MCED.
• Two distinct data sources drive treatment patterns:
• Treatment flags for surgery, radiotherapy, and SACT were generated from national datasets (NDRS, RTDS, SACT, inpatient and outpatient HES).
• Cancer incidence by stage, for England (2014–2019), provided the baseline on which the MCED-induced stage shifts could be imposed.
• The treatment modalities were treated as non-mutually exclusive; a tumour could be counted in more than one category.
• Treatment intent (curative vs palliative) was inferred from the earliest SACT regimen or RTDS appointment when available.
• The interception model applied to estimate stage-specific incidence shifts due to MCED screening, integrating cancer-type and stage-specific sensitivities to Galleri MCED, and dwell times that reflect typical progression through stages (with cancers spending 1–2 years in stage I).
• Two variations of stage-adjusted incidence were used:
• An initial screening round (prevalent screen) reflecting first exposure in the 50–79 age bracket.
• A steady-state programme with annual screening from ages 50–79, applying age-specific incidence rates each year and accumulating intercepted cancers at each stage according to MCED sensitivity and dwell-time assumptions.
• The primary analytical approach was to apply the stage-shifted cancer incidence data (post-MCED interception) to the existing treatment-pattern proportions by modality.

The reported aggregate figure for the steady-state scenario is a modest relative increase in resections (+10.0%), corresponding to an absolute increase of approximately 8,900 surgeries across all cancers.

This follows from higher detected incidence at earlier stages where surgical resection is more commonly indicated.

This reduction principally stems from a decline in palliative radiotherapy (−2,100; −23.0%).

In contrast, curative radiotherapy would show a small uptick (+932; +2.1%), reflecting a shift toward curative-intent radiotherapy in a context of earlier detection for some cancer types.

The delineation implies a net overall reduction in systemic therapy utilization, though the interplay with more frequent surgical resections could modulate overall patient experience and plan.

In particular, there is an implied rise in cases receiving curative combinations (e.g., resection plus radiotherapy and/or SACT) relative to the pre-MCED baseline.

A 100% participation scenario demonstrates the theoretical maximum shift in treatments, illustrating the potential scale of change but not predicting realistic adherence.

• Across the 19 cancer types and after the initial introduction of MCED screening (the first screen) as well as under a steady-state programme, the model projects specific directional changes in treatment volumes:
• Surgical resections: an overall increase in the number of cancers treated with resection compared with current annual usage, with a pronounced rise in the steady-state scenario.
• Radiotherapy: a net decrease in the total number of cancers treated with radiotherapy, estimated at around 1,200 fewer patients (−2.0%).
• Systemic anti-cancer therapy (SACT): a broad reduction in use, with cytotoxic SACT decreasing by about 5,300 cases (−9.8%) and non-cytotoxic SACT decreasing by about 530 cases (−12.2%).
• The model also anticipates increased adoption of treatment regimens with curative intent that combine modalities.
• The authors note that the actual realization of mortality benefits hinges on timely and appropriate treatment following MCED-detected cancer, given that prognosis and treatment options are highly contingent on cancer type and stage, patient characteristics, and the availability of evolving therapies, including targeted and immunotherapy approaches.
• The study explicitly acknowledges the current late-stage cancer burden in England (approximately 46% diagnosed at late stage since 2013) and frames MCED as a potential means to reduce late-stage incidence, with the understanding that substantial changes in service delivery and workforce planning would be necessary to capture the full benefits of MCED-enabled early detection.
• The analysis highlights that the effect on treatment volumes is sensitive to participation rates and the assumed effectiveness of MCED in intercepting cancers at earlier stages.

The authors signal that observed treatment patterns are stage-specific and context-driven, and that the application of stage-shifted incidence to current modality distributions assumes that treatment choices align with standard-of-care practices observed in the historical data.

They also acknowledge that several cancers may not be equally amenable to early detection or to the same degree of stage shifting, and that the precise magnitude of workforce and service delivery changes will depend on actual participation and the effectiveness of MCED in real-world settings.

• The modelling rests on several foundational premises:
• MCED detection is assumed to reclassify a fraction of cancers as earlier-stage at diagnosis, thereby altering the distribution of stage at presentation relative to current care pathways.
• The treatment landscape by stage for the 19 cancers is applied to the MCED-altered stage distribution, enabling estimation of how many cancers would be managed with specific modalities if MCED screening were implemented.
• The data sources are national and comprehensive, spanning tumour-level treatment events and patient-level treatment regimens, with careful attention to excluding multiple counts for the same tumour when constructing modality flags.
• The study draws on the NHS-Galleri trial and broader literature to set expectations about screening performance and potential reductions in late-stage incidence, while clearly stating that real-world mortality benefits depend on treatment optimization following diagnosis.
• Limitations are inherent in any modelling exercise of this type.

This includes alignment of screening uptake with diagnostic and treatment services, ensuring timely access to cure-directed therapies, and adjusting workforce deployment to reflect new patterns of care.

• The projected shifts in treatment demand imply downstream implications for healthcare delivery and workforce planning:
• An uptick in surgical resections across the cancer spectrum would necessitate expanded surgical capacity, pathology, perioperative care, and potential modifications to operating theatre scheduling and post-operative resources.
• A relative decline in radiotherapy, especially palliative radiotherapy, might reallocate radiotherapy resources toward curative-intent pathways and earlier-stage disease management, potentially altering the mix and scheduling of radiotherapy facilities, staffing, and equipment utilization.
• The observed reductions in cytotoxic and non-cytotoxic SACT use point to changes in systemic therapy demand, with implications for infusion centers, pharmacy supply chains, and follow-up care pathways.
• The authors emphasise that to realize the advantages of MCED screening, healthcare systems would need to anticipate and plan for shifting cancer care demand.
• The broader clinical context notes that the introduction of MCED alongside existing programs could alter the balance of stage distribution and treatment burden, underscoring the need for integrated service design that accounts for potential early detection-driven volume changes.

• The study explicitly notes uncertainties related to:
• The accuracy of MCED test parameters (sensitivity and specificity by cancer type and stage) as used in the interception model, since these feed directly into predicted stage shifts and subsequent treatment demands.
• The assumption of 70% participation in MCED screening, with an additional scenario at 100% participation, which affects the scale of predicted stage shifts and subsequent treatment changes.
• The transferability of current treatment-by-stage patterns to cancers detected at earlier stages through MCED; real-world treatment choices may deviate due to evolving guidelines, patient preferences, and the employment of newer therapies.
• The potential variability in stage-specific interception across cancer types, given heterogeneity in tumor biology, screening detectability, and patient comorbidity profiles that influence treatment feasibility.
• The report acknowledges substantial uncertainty around the extent to which MCED screening can translate into mortality reductions, emphasizing that stage shifts are a necessary but not solely sufficient condition for improved outcomes; they must be paired with timely, effective treatment delivery.
• The data reflect England-specific patterns for 2014–2019; extrapolation to current or future practice requires caution, given evolving coding, treatment modalities, and service structures, as well as changes in population health dynamics and screening uptake.

• The analysis could not determine treatment intent for all cases where multiple tumours were diagnosed within the 18-month window, which introduces some ambiguity in categorizing curative versus palliative treatment for those patients.
• Detailed radiotherapy dose, fractionation, or the exact number of SACT regimens per tumour were not available, limiting granular assessment of treatment intensity and sequencing.
• The modelling framework assumes that MCED-detected cancers would receive treatment regimens consistent with current standard-of-care practices by cancer type and stage, a simplifying assumption that may not capture future shifts in therapeutic guidelines or novel regimens emerging in response to early detection data.
• The study does not report cancer-type–specific results in detail within the text excerpt; the headline statement highlights major contributions from lung, colon, rectal, and head-and-neck cancer resection increases, but full type-by-type breakdown is not provided here.

They also underscore that realizing potential mortality and quality-of-life benefits hinges on translating earlier detection into timely, appropriate, and effective treatment pathways.

It highlights that substantial innovation and resource planning would be required to accommodate future care patterns if MCED screening were offered alongside existing screening programs.

• The analysis provides a structured projection that introducing MCED screening in England could re-balance cancer treatment modalities across the 19 detectable cancers, with a notable predicted rise in surgical resections and a broad reduction in systemic therapies, accompanied by a modest decline in overall radiotherapy use chiefly from fewer palliative radiotherapy cases.
• The results emphasize that the magnitude of these changes depends on the degree of stage shift produced by MCED detection, participation rates, and the ability of health services to adapt to altered demand.
• The study frames its findings as a basis for strategic planning rather than a demonstration of clinical efficacy.